DiaMedica Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for DiaMedica Therapeutics Inc. (DMAC) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-24.44-19.38-13.68-13.59-12.29-10.65-5.73
Depreciation & Amortization0.040.030.030.020.02-0.050.02
Stock Based Compensation2.091.681.501.561.840.000.00
Change in Working Capital1.510.090.59-0.461.200.39-0.64
Change in Accounts Receivable0.13-0.290.050.210.480.000.00
Change in Accounts Payable0.010.190.23-0.590.920.000.00
Change in Other Working Capital1.370.070.060.06-0.210.000.00
Other Operating Activities-1.270.070.061.621.901.210.00
Net Cash from Operating Activities-22.08-18.73-11.51-12.25-9.19-9.10-5.70
Investing Activities
Capital Expenditures-0.03-0.02-0.080.020.050.00-0.05
Purchases of Investments-50.41-69.41-45.68-69.81-16.100.000.00
Sales/Maturities of Investments59.0051.1457.30-20.52-16.10-3.920.00
Net Cash from Investing Activities8.56-18.3011.54-20.54-16.13-3.91-0.05
Financing Activities
Debt Repayment-0.01-0.01-0.01-0.010.000.000.00
Common Stock Issued11.7536.850.0029.8528.810.0020.57
Other Financing Activities0.260.000.00-0.150.0016.820.00
Net Cash from Financing Activities11.9936.84-0.0130.0928.850.0721.22
Summary
Net Change in Cash-1.52-0.190.02-2.703.53-12.9415.47
Cash at Beginning of Period4.544.734.717.413.8816.821.35
Cash at End of Period3.034.544.734.717.4120.7116.82
Free Cash Flow-22.10-18.75-11.59-12.27-9.22-9.09-5.75
Supplemental Disclosures
Interest Paid0.000.000.000.000.000.000.01
Income Taxes Paid0.030.030.030.030.040.030.08